{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_13756", "batch_size": 200, "batch_pos": 89, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 2, "answer": "no", "rationale": "The verb 'climbed' describes stock price movement, not the threat's impact, and is not high-potency in this context.", "method": "llm_batch", "batch_id": "batch_2_16852", "batch_size": 200, "batch_pos": 83, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 3, "answer": "no", "rationale": "'climbed' is a moderate verb + scale, but refers to financial metrics, which are Neutral.", "method": "llm_batch", "batch_id": "batch_3_16228", "batch_size": 200, "batch_pos": 75, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_18692", "batch_size": 200, "batch_pos": 71, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 5, "answer": "no", "rationale": "The segment reports stock movement and potential funding, not explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_96", "batch_size": 200, "batch_pos": 69, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 6, "answer": "no", "rationale": "No minimiser or scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_14220", "batch_size": 200, "batch_pos": 59, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 7, "answer": "uncertain", "rationale": "LLM call failed.", "method": "llm_batch", "batch_id": "batch_7_14876", "batch_size": 200, "batch_pos": 56, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 8, "answer": "yes", "rationale": "The segment mentions 'deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine', describing a development capability/future possibility without active reassurance.", "method": "llm_batch", "batch_id": "batch_8_14824", "batch_size": 200, "batch_pos": 32, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
